A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia
NCT ID: NCT00629681
Last Updated: 2021-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
217 participants
INTERVENTIONAL
2004-11-30
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)
NCT00156078
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
NCT00553280
Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT00143156
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain
NCT01455415
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
NCT00407511
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Pregabalin
Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregabalin
Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Score on the Numeric Rating Scale of at least 4/10
Exclusion Criteria
* Neurologic disorders unrelated to DPN or PHN or any severe pain that may confound the assessment of DPN- or PHN-related pain
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Aachen, , Germany
Pfizer Investigational Site
Albstadt, , Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Bielefeld, , Germany
Pfizer Investigational Site
Celle, , Germany
Pfizer Investigational Site
Deggingen, , Germany
Pfizer Investigational Site
Duisburg, , Germany
Pfizer Investigational Site
Erbach im Odenwald, , Germany
Pfizer Investigational Site
Erfurt, , Germany
Pfizer Investigational Site
Frankfurt, , Germany
Pfizer Investigational Site
Gera, , Germany
Pfizer Investigational Site
Göppingen, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Hemsbach, , Germany
Pfizer Investigational Site
Hildesheim, , Germany
Pfizer Investigational Site
Holle, , Germany
Pfizer Investigational Site
Itzehoe, , Germany
Pfizer Investigational Site
Karlsruhe, , Germany
Pfizer Investigational Site
Karlsruhe, , Germany
Pfizer Investigational Site
Katzhütte, , Germany
Pfizer Investigational Site
Leer, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Limburgerhof, , Germany
Pfizer Investigational Site
Ludwigshafen, , Germany
Pfizer Investigational Site
Ludwigshafen, , Germany
Pfizer Investigational Site
Lübeck, , Germany
Pfizer Investigational Site
Lünen, , Germany
Pfizer Investigational Site
Mainz, , Germany
Pfizer Investigational Site
Marl, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Münster, , Germany
Pfizer Investigational Site
Osnabrück, , Germany
Pfizer Investigational Site
Recklinghausen, , Germany
Pfizer Investigational Site
Senftenberg, , Germany
Pfizer Investigational Site
Sinsheim, , Germany
Pfizer Investigational Site
Surwold, , Germany
Pfizer Investigational Site
Unterhaching, , Germany
Pfizer Investigational Site
Veitsbronn, , Germany
Pfizer Investigational Site
Weimar, , Germany
Pfizer Investigational Site
Wiesbaden, , Germany
Pfizer Investigational Site
Witten, , Germany
Pfizer Investigational Site
Zwönitz, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A0081031
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.